21. Experimental study on cabling properties of different REBCO coated tapes. (June 2020) Authors: Xiao, G Y; Liu, F; Jin, H; Zhou, C; Qin, J G; Liu, H J; Li, J G; Dai, T L; Zhang, X T Journal: Journal of physics Issue: Volume 1559(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. Experiments and FE modeling of stress–strain state in ReBCO tape under tensile, torsional and transverse load. (24th March 2015) Authors: Ilin, K; Yagotintsev, K A; Zhou, C; Gao, P; Kosse, J; Otten, S J; Wessel, W A J; Haugan, T J; van der Laan, D C; Nijhuis, A Journal: Superconductor science & technology Issue: Volume 28:Number 5(2015:May) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. (31st December 2018) Authors: Wang, Y; Jiang, T; Qin, Z; Jiang, J; Wang, Q; Yang, S; Rivard, C; Gao, G; Ng, T L; Tu, M M; Yu, H; Ji, H; Zhou, C; Ren, S; Zhang, J; Bunn, P; Doebele, R C; Camidge, D R; Hirsch, F R Journal: Annals of oncology Issue: Volume 30:Number 3(2019) Page Start: 447 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. Integrated omics analysis of sweat reveals an aberrant amino acid metabolism pathway in Vogt–Koyanagi–Harada disease. (14th April 2020) Authors: Cui, X; Su, G; Zhang, L; Yi, S; Cao, Q; Zhou, C; Kijlstra, A; Yang, P Journal: Clinical and experimental immunology Issue: Volume 200:Number 3(2020) Page Start: 250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. LBA10Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC. (23rd October 2018) Authors: Zhou, C; Lu, Y; Kim, S-W; Reungwetwattana, T; Zhou, J; Zhang, Y; He, J; Yang, J-J; Cheng, Y; Lee, S H; Bu, L; Xu, T; Yang, L; Wang, C; Morcos, P N; Mitry, E; Liu, T; Zhang, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. LBA16Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. (24th November 2019) Authors: Cho, B C; Ohe, Y; Zhou, C; Reungwetwattana, T; Cheng, Y; Chewaskulyong, B; Lee, K H; Planchard, D; Vansteenkiste, J F; Gray, J E; Shah, R; Cheema, P K; Tiseo, M; John, T; Hodge, R; Rukazenkov, Y; Soria, J-C; Lin, M-C; Imamura, F; Ramalingam, S S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. LBA2Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC). (25th November 2018) Authors: Zhou, C; Lu, Y; Kim, S-W; Reungwetwattana, T; Zhou, J; Zhang, Y; He, J; Yang, J-J; Cheng, Y; Lee, S H; Bu, L; Xu, T; Yang, L; Wang, C; Morcos, P N; Mitry, E; Li, Z Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. (23rd October 2018) Authors: Ramalingam, S S; Cheng, Y; Zhou, C; Ohe, Y; Imamura, F; Cho, B C; Lin, M-C; Majem, M; Shah, R; Rukazenkov, Y; Todd, A; Markovets, A; Barrett, J C; Chmielecki, J; Gray, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. LBA8Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. (25th November 2018) Authors: Cho, B C; Cheng, Y; Zhou, C; Ohe, Y; Imamura, F; Lin, M-C; Majem, M; Shah, R; Rukazenkov, Y; Todd, A; Markovets, A; Barrett, C; Chmielecki, J; Gray, J E; Ramalingam, S S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine. (January 2019) Authors: Zhang, S; Liu, X; Cai, L; Zhang, J; Zhou, C Journal: Lupus Issue: Volume 28:Number 1(2019) Page Start: 129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗